Infectious disease
Axcella announced it is initiating a new clinical program to study AXA1125 in patients with Long Covid. The trial will be conducted at the Oxford Centre for Clinical Magnetic Resonance Research.
If the panel votes in favor of the vaccine for children, it will move to the U.S. CDC. If both agencies support the data, children this age would be likely to receive their first shots in early November.
Initial results showed a strong neutralizing antibody response and favorable safety profile among the participants.
Some fear potential side effects, and more just aren’t sure about the quality and risks associated with a vaccine developed in an unprecedented nine months.
The U.S. Food and Drug Administration posted analyses of the Pfizer-BioNTech COVID-19 vaccine in children ages 5 to 11 years old ahead of Tuesday’s vaccines advisory committee meeting.
It was yet another busy week for clinical trial news. Here’s a look.
A growing number of studies show that though natural immunity can work, hybrid immunity through vaccination could be better. They urge faster vaccination drives.
Earlier this month, Catalent announced plans to add 500–600 jobs in Bloomington, Ind., one of its Moderna and Johnson & Johnson COVID-19 vaccine manufacturing sites.
The CDC supported the FDA’s approval of mixing and matching vaccines, where eligible populations can take a booster shot from another brand different from their initial series.
The Pfizer-BioNTech mRNA COVID-19 vaccine is reportedly the top vaccine used globally. Here’s a look at today’s highlights.
PRESS RELEASES